(ANRO) Alto Neuroscience - Overview

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US02157Q1094

Stock: Antidepressant, Cognitive, Schizophrenia, Depression, Clinical

Total Rating 44

Risk 67

Buy Signal 0.08

Biotechnology » Pharmaceuticals
Age: 2y

Market Cap: 491m
Avg Trading Vol: 2.74M USD

ATR: 8.63%
Peers RS (IBD): 92.78

EPS (Earnings per Share)

EPS CAGR: 1042.37%
EPS Trend: 68.1%

Last SUE: 0.31
Qual. Beats: 0

Revenue

Rev. CAGR: 0.00%
Rev. Trend: 7.2%

Qual. Beats: 0

Risk 5d forecast
Volatility	90.2%
Relative Tail Risk	-8.32%

Reward TTM
Sharpe Ratio	1.54
Alpha	246.21

Character TTM
Beta	1.046
Beta Downside	1.603

Drawdowns 3y
Max DD	91.74%
CAGR/Max DD	-0.03

Description: ANRO Alto Neuroscience December 22, 2025

Alto Neuroscience, Inc. (NYSE: ANRO) is a clinical-stage biopharma firm founded in 2019 and based in Mountain View, California, focused on small-molecule therapeutics for neuropsychiatric disorders.

The company’s pipeline consists of five candidates: ALTO-100 (Phase 2b for bipolar depression), ALTO-300 (Phase 2b for major depressive disorder), ALTO-101 (Phase 2 proof-of-concept for cognitive impairment in schizophrenia), ALTO-203 (Phase 2 POC for MDD with high anhedonia), and ALTO-202 (Phase 1 for MDD as an oral GluN2B antagonist).

Key sector drivers include a global antidepressant market valued at roughly $30 billion and a growing demand for novel mechanisms of action, while historical Phase 2 success rates in CNS therapeutics hover around 30 %, underscoring the risk-reward profile of Alto’s programs. As of the latest filing, the company reported a cash runway of about $45 million, giving it roughly 12-month liquidity at its current burn rate of $15 million per quarter.

For a deeper, data-rich perspective on Alto’s valuation and comparable peers, you might explore the analyst tools on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income: -62.3m TTM > 0 and > 6% of Revenue
FCF/TA: -0.37 > 0.02 and ΔFCF/TA -11.63 > 1.0
NWC/Revenue: 33.1k% < 20% (prev 45.6k%; Δ -12.5k% < -1%)
CFO/TA -0.36 > 3% & CFO -53.3m > Net Income -62.3m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 15.42 > 1.5 & < 3
Outstanding Shares: last quarter (27.1m) vs 12m ago 0.54% < -2%
Gross Margin: -53.55% > 18% (prev -0.31%; Δ -5324 % > 0.5%)
Asset Turnover: 0.23% > 50% (prev 0.19%; Δ 0.04% > 0%)
Interest Coverage Ratio: -26.96 > 6 (EBITDA TTM -59.4m / Interest Expense TTM 2.23m)

Altman Z'' -6.17

A: 0.89 (Total Current Assets 139.4m - Total Current Liabilities 9.04m) / Total Assets 147.0m
B: -1.26 (Retained Earnings -185.5m / Total Assets 147.0m)
C: -0.35 (EBIT TTM -60.0m / Avg Total Assets 169.3m)
D: -5.23 (Book Value of Equity -185.4m / Total Liabilities 35.4m)
Altman-Z'' Score: -6.17 = D

What is the price of ANRO shares?

As of February 08, 2026, the stock is trading at USD 15.22 with a total of 274,277 shares traded.
Over the past week, the price has changed by -1.68%, over one month by +0.93%, over three months by +36.75% and over the past year by +285.32%.

Is ANRO a buy, sell or hold?

Alto Neuroscience has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy ANRO.

StrongBuy: 6
Buy: 1
Hold: 1
Sell: 0
StrongSell: 0

What are the forecasts/targets for the ANRO price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	31.1	104.5%
Analysts Target Price	31.1	104.5%
ValueRay Target Price	18	18.4%

ANRO Fundamental Data Overview February 04, 2026

P/B = 4.2663
Revenue TTM = 394.0k USD
EBIT TTM = -60.0m USD
EBITDA TTM = -59.4m USD
Long Term Debt = 22.4m USD (from longTermDebt, last quarter)
Short Term Debt = 1.12m USD (from shortTermDebt, last quarter)
Debt = 27.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -110.3m USD (from netDebt column, last quarter)
Enterprise Value = 380.9m USD (491.2m + Debt 27.5m - CCE 137.8m)
Interest Coverage Ratio = -26.96 (Ebit TTM -60.0m / Interest Expense TTM 2.23m)
EV/FCF = -7.08x (Enterprise Value 380.9m / FCF TTM -53.8m)
FCF Yield = -14.13% (FCF TTM -53.8m / Enterprise Value 380.9m)
FCF Margin = -13.7k% (FCF TTM -53.8m / Revenue TTM 394.0k)
Net Margin = -15.8k% (Net Income TTM -62.3m / Revenue TTM 394.0k)
Gross Margin = -53.55% ((Revenue TTM 394.0k - Cost of Revenue TTM 605.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 2.59 (Enterprise Value 380.9m / Total Assets 147.0m)
Interest Expense / Debt = 2.36% (Interest Expense 650.0k / Debt 27.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -47.4m (EBIT -60.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 15.42 (Total Current Assets 139.4m / Total Current Liabilities 9.04m)
Debt / Equity = 0.25 (Debt 27.5m / totalStockholderEquity, last quarter 111.6m)
Debt / EBITDA = 1.86 (negative EBITDA) (Net Debt -110.3m / EBITDA -59.4m)
Debt / FCF = 2.05 (negative FCF - burning cash) (Net Debt -110.3m / FCF TTM -53.8m)
Total Stockholder Equity = 131.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -36.77% (Net Income -62.3m / Total Assets 147.0m)
RoE = -47.39% (Net Income TTM -62.3m / Total Stockholder Equity 131.4m)
RoCE = -39.03% (EBIT -60.0m / Capital Employed (Equity 131.4m + L.T.Debt 22.4m))
RoIC = -31.47% (negative operating profit) (NOPAT -47.4m / Invested Capital 150.7m)
WACC = 9.35% (E(491.2m)/V(518.7m) * Re(9.77%) + D(27.5m)/V(518.7m) * Rd(2.36%) * (1-Tc(0.21)))
Discount Rate = 9.77% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.41%
Fair Price DCF = unknown (Cash Flow -53.8m)
EPS Correlation: 68.09 | EPS CAGR: 1042 % | SUE: 0.31 | # QB: 0
Revenue Correlation: 7.19 | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.48 | Chg30d=N/A | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=-2.13 | Chg30d=N/A | Revisions Net=+0 | Growth EPS=+9.4% | Growth Revenue=+0.0%

Additional Sources for ANRO Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle